Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Assembly Biosciences (ASMB) EBIT Margin (2017 - 2025)

Assembly Biosciences has reported EBIT Margin over the past 8 years, most recently at 46.62% for Q4 2025.

  • Quarterly results put EBIT Margin at 46.62% for Q4 2025, up 20337.0% from a year ago — trailing twelve months through Dec 2025 was 16.76% (up 14250.0% YoY), and the annual figure for FY2025 was 16.76%, up 14250.0%.
  • EBIT Margin for Q4 2025 was 46.62% at Assembly Biosciences, up from 100.87% in the prior quarter.
  • Over the last five years, EBIT Margin for ASMB hit a ceiling of 46.62% in Q4 2025 and a floor of 301.81% in Q3 2021.
  • Median EBIT Margin over the past 4 years was 149.88% (2024), compared with a mean of 139.73%.
  • Biggest five-year swings in EBIT Margin: tumbled -29019bps in 2021 and later skyrocketed 20337bps in 2025.
  • Assembly Biosciences' EBIT Margin stood at 301.81% in 2021, then skyrocketed by 42bps to 175.22% in 2023, then grew by 11bps to 156.75% in 2024, then surged by 130bps to 46.62% in 2025.
  • The last three reported values for EBIT Margin were 46.62% (Q4 2025), 100.87% (Q3 2025), and 115.24% (Q2 2025) per Business Quant data.